Back to search

Article

Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPP

2022-06-06

Abstract excerpt

<h4>Background</h4> The UK COVID-19 vaccination programme delivered its first “booster” doses in September 2021, initially in groups at high risk of severe disease then across the adult population. The BNT162b2 Pfizer-BioNTech vaccine was used initially, with Moderna mRNA-1273 subsequently also used. <h4>Methods</h4> We used the OpenSAFELY-TPP database, covering 40% of English primary care practices and linked to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
be58e655-cf76-514c-b166-6f13568b719f
DOI
10.1101/2022.06.06.22276026
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPPDOI 10.1101/2022.06.06.22276026
Comparative effectiveness of BNT162b2 versus mRNA-1273 boosting in England: a cohort study in OpenSAFELY-TPPSemantic proximity
Comparative effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections: A time-varying cohort analysis using trial emulation in the Virus Watch community cohortSemantic proximity
COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial Evidence on the Omicron Variant)Semantic proximity
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccinesSemantic proximity
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in EnglandSemantic proximity
Comparative effectiveness of ChAdOx1 versus BNT162b2 vaccines against SARS-CoV-2 infections in England and Wales: A cohort analysis using trial emulation in the Virus Watch community dataSemantic proximity
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarSemantic proximity
Twelve-month follow-up of immunogenicity and safety of fractional and standard booster doses of the Pfizer-BioNTech COVID-19 vaccine in adults primed with ChAdOx1, BBIBP-CorV, or GAM-CoV-Vac: a randomised controlled trialSemantic proximity
Reported Effectiveness of COVID-19 Booster Vaccines: A Systematic Review of Early Literature and Implications for Emerging Vaccination PolicySemantic proximity
BNT162B2 mRNA Covid-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in the Medium - to Long-Term: A Retrospective Cohort StudySemantic proximity
Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 MonthsSemantic proximity
Select a neighboring publication to make it the new centre.